‘Momentum continues to strengthen’: Burjeel’s Dr Shamsheer Vayalil on H1 2026
Chairman and CEO Dr Shamsheer Vayalil talks about the milestones behind the results, his priorities for H2, and where UAE healthcare and AI’s role within it go next
11 August, 2026
TT
16
Fresh from a first half marked by accelerating patient volumes, margin expansion and a landmark $500m debut sukuk, Burjeel Holdings is entering the year’s second half with momentum. Chairman and CEO Dr Shamsheer Vayalil talks to Gulf Business about the milestones behind the results, his priorities for H2, and where UAE healthcare and AI’s role within it go next.
Beyond the financial performance, what were the most significant operational milestones or achievements for Burjeel Holdings during the first half of the year?
Beyond the financials, H1 truly embodied our commitment to action and resilience. Despite a challenging regional backdrop, we maintained uninterrupted care across our network while continuing to invest in capabilities that support the UAE’s healthcare ambitions.
Key milestones included the launch of the Burjeel Breast Center and its One-Stop Breast Clinic model, designed to significantly reduce the time between diagnosis and treatment; the opening of the Korean Pavilion at Burjeel Hospital Abu Dhabi, creating new pathways for patients to access world-class Korean medical expertise closer to home; the launch of Tajmeel’s flagship centre in Jumeirah; and the expansion of our community healthcare footprint through a new Burjeel Medical Centre in Dubai Silicon Oasis.
We also strengthened the foundations for our next phase of growth through our landmark inaugural $500m sukuk issuance, which was met with strong investor demand and reinforced confidence in our long-term strategy. Together, these milestones reflect our commitment to expanding access to specialised care, investing in innovation, and supporting the UAE’s vision for a world-class healthcare ecosystem.
As Burjeel Holdings enters the second half of the year, what key trends from H1 are shaping your priorities and areas of focus?
What H1 demonstrated is that the underlying momentum of the business continues to strengthen. In the second quarter, we saw a meaningful acceleration in patient volumes, continued recovery in complex and elective procedures, and another quarter of margin expansion, reflecting both healthy demand and disciplined execution.
As we enter the second half of the year, our priorities remain clear. First, we will continue driving market penetration across our core markets by expanding access to our integrated healthcare network and increasing the contribution from recently opened facilities. Second, we remain focused on improving operational efficiency through procurement optimisation, disciplined cost management, and operating leverage as our newer assets continue to mature.
At the same time, we will continue investing selectively in our clinical capabilities, particularly in complex specialities such as oncology, transplant medicine and precision care, while strengthening our digital and AI capabilities. We believe this balanced approach, combining sustainable growth with continued efficiency improvements, positions us well to deliver another year of profitable growth and long-term value creation.
How do you see the UAE’s healthcare sector evolving over the next five years, and what role will private healthcare providers play in supporting the country’s healthcare ambitions?
Over the next five years, the UAE healthcare sector is moving from strong infrastructure to deeper clinical capability, in line with We the UAE 2031 and its focus on accessible, high-quality, preventive and data-driven care. Private providers have to support that shift by investing in advanced treatments, qualified talent, digital infrastructure, research, and centres of excellence.
At Burjeel, our role is to help make complex, personalised care available closer to home, while supporting the UAE’s ambition to become a trusted global destination for healthcare.
How is artificial intelligence moving from a future concept to a practical healthcare tool, and where do you believe it can create the biggest impact for patients and providers alike?
AI is no longer a future concept in healthcare. It is already supporting faster diagnostics, clinical decision-making, patient monitoring and workflow efficiency, particularly in areas such as imaging, pathology, treatment planning and hospital operations.
At Burjeel, we are now live with the Oracle Health Clinical AI Agent, bringing AI-powered ambient listening into outpatient care workflows. This is a practical example of how AI can reduce administrative burdens and allow clinicians to focus more fully on patients.
The real value of AI is not in replacing clinicians, but in giving them better tools to diagnose earlier, act faster, improve treatment planning, and use healthcare resources more effectively.
The UAE is increasingly recognised as a destination for specialised and complex care. What factors are contributing to this rise, and how can the country further strengthen its position as a global healthcare hub?
The UAE has already built the infrastructure, connectivity and trust needed to serve patients from across the region. What comes next is stronger clinical outcomes, complex care, research, medical education and greater system resilience.
We are working closely with global partners to bring international expertise closer to patients in the UAE. Private providers must support this shift through talent, advanced treatments, partnerships, digital capability and readiness.

























